Zaniducla
(Zanidatamab)Phase 3Monoclonal antibody
Jazz PharmaceuticalsZanidatamab is used to treat certain types of stomach cancer and gastroesophageal junction cancer in patients whose tumors have specific genetic characteristics (HER2 positivity). It works by targeting and blocking cancer cells that have too much of a protein called HER2.[1] Zaniducla is currently being investigated across 13 indications[3], with its most advanced program in Phase 3.[1]
Zaniducla is one of 208 biologic programs targeting HER2 Positive. It is currently in Phase 3.
13
Indications
24
Total Trials
21
Active Trials
207
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Zaniducla
Jazz PharmaceuticalsPhase 3
Voltaren
NovartisPreclinical
Lexiscan
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Rilvegostomig
AstraZenecaPreclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer5 trials
Gastroesophageal Adenocarcinoma3 trials
HER2 Positive2 trials
Biliary Tract Cancer2 trials
10 more indications
Advanced Malignancies1 trial
Patients With Solid Tumors1 trial
Colon and Rectal Cancer1 trial
Metastatic Breast Cancer1 trial
Gastric Neoplasms1 trial
Esophageal Cancer1 trial
Biliary Tract Cancer (BTC)1 trial
Gastric Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zanidatamab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Receptor Protein-Tyrosine Kinase Erbb-2 Inhibitor[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company